A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects
Latest Information Update: 30 Aug 2021
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Acute heart failure; Chronic heart failure; Heart failure
- Focus Pharmacokinetics
- Sponsors Cytokinetics
- 20 Aug 2021 Results of two clinical studies evaluating pharmacokinetics, tolerability, and safety of single and multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian subjects published in the European Journal of Drug Metabolism and Pharmacokinetics
- 27 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.